Javascript must be enabled to continue!
How Reliable Is the High-Volume Definition in Prostate Cancer Patients: The Potential Game-Changing Role of PSMA
View through CrossRef
Abstract
Purpose
To evaluate whether metabolic and volumetric data from Ga-68 PSMA PET CT performed during staging of denovo high-volume mCSPC patients who received docetaxel could be used to predict survival.
Methods
Forty-two denovo high-volume metastatic castration-sensitive prostate cancer patients, who received ADT + Docetaxel and underwent Ga-68 PSMA PET CT for staging, were included in the study. The association between patients' pathological data, all PSA measurements, treatments they received, and the data obtained from Ga-68 PSMA PET CT and progression-free and overall survival were examined. In the univariant analysis performed with the log-rank test, it was evaluated whether the difference between subgroups of variables was statistically significant in terms of survival. Variables found statistically significant were included in the multivariate analysis with the Cox hazard ratio model.
Results
In the multivariate analysis, PSMA-TV (primary) and PSMA-TV (WB) variables were shown to be independent negative predictors of overall survival. For the threshold value of 19.91 cc obtained for PSMA-TV (primary), HR was calculated as 6.31, 95% CI: 1.01-39.18, p: 0.048. For the threshold value of 1226.5 cc obtained for PSMA-TV(WB) variable, HR was calculated as 58.62, 95% CI: 2.55-1344.43, p:0.011. In our study, SUVmax (WB) variable was found to be an independent and negative predictor of progression-free survival. For the determined threshold value of 17.74, HR was calculated as 16.24, 95% CI: 1.18-22.76, p: 0.037.
Conclusion
Metabolic and volumetric data obtained from Ga-68 PSMA PET CT can be used to predict survival in denovo high-volume mCSPC. Our results show that ADT + Docetaxel receiving patients with high PSMA-TV (WB) values have a significantly worse prognosis. This situation reveals that the high-volume disease definition in the literature is insufficient for this group and that Ga-68 PSMA PET CT can play an important role in demonstrating the heterogeneity within the group.
Springer Science and Business Media LLC
Title: How Reliable Is the High-Volume Definition in Prostate Cancer Patients: The Potential Game-Changing Role of PSMA
Description:
Abstract
Purpose
To evaluate whether metabolic and volumetric data from Ga-68 PSMA PET CT performed during staging of denovo high-volume mCSPC patients who received docetaxel could be used to predict survival.
Methods
Forty-two denovo high-volume metastatic castration-sensitive prostate cancer patients, who received ADT + Docetaxel and underwent Ga-68 PSMA PET CT for staging, were included in the study.
The association between patients' pathological data, all PSA measurements, treatments they received, and the data obtained from Ga-68 PSMA PET CT and progression-free and overall survival were examined.
In the univariant analysis performed with the log-rank test, it was evaluated whether the difference between subgroups of variables was statistically significant in terms of survival.
Variables found statistically significant were included in the multivariate analysis with the Cox hazard ratio model.
Results
In the multivariate analysis, PSMA-TV (primary) and PSMA-TV (WB) variables were shown to be independent negative predictors of overall survival.
For the threshold value of 19.
91 cc obtained for PSMA-TV (primary), HR was calculated as 6.
31, 95% CI: 1.
01-39.
18, p: 0.
048.
For the threshold value of 1226.
5 cc obtained for PSMA-TV(WB) variable, HR was calculated as 58.
62, 95% CI: 2.
55-1344.
43, p:0.
011.
In our study, SUVmax (WB) variable was found to be an independent and negative predictor of progression-free survival.
For the determined threshold value of 17.
74, HR was calculated as 16.
24, 95% CI: 1.
18-22.
76, p: 0.
037.
Conclusion
Metabolic and volumetric data obtained from Ga-68 PSMA PET CT can be used to predict survival in denovo high-volume mCSPC.
Our results show that ADT + Docetaxel receiving patients with high PSMA-TV (WB) values have a significantly worse prognosis.
This situation reveals that the high-volume disease definition in the literature is insufficient for this group and that Ga-68 PSMA PET CT can play an important role in demonstrating the heterogeneity within the group.
Related Results
Abstract B054: Phase 1 study of 61Cu-NU101 in patients with prostate cancer
Abstract B054: Phase 1 study of 61Cu-NU101 in patients with prostate cancer
Abstract
Background:
Prostate Specific Membrane Antigen (PSMA)-targeted Positron Emission Tomography (PET) has revolution...
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
Abstract
Background
Differentiated thyroid carcinoma (DTC) is the most common type of thyroid cancer. Treatment with surgery, radioactive iodine (RAI), and TSH suppression is effec...
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
Abstract
Background
Routine prostate-specific membrane antigen (PSMA) positron emission tomography (PET) performed for primary staging or restaging ...
68Ga-PSMA-11 PET/CT Imaging in Brain Gliomas and Its Correlation With Clinicopathological Prognostic Parameters
68Ga-PSMA-11 PET/CT Imaging in Brain Gliomas and Its Correlation With Clinicopathological Prognostic Parameters
Background
Gliomas are the most common primary central nervous system tumors, of which the malignant gliomas account for 60%–75%. The primary and secondary brain malign...
Data from Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies
Data from Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies
<div>Abstract<p>Targeted imaging and therapy approaches based on novel prostate-specific membrane antigen (PSMA) inhibitors have fundamentally changed the treatment reg...
Abstract 4602: Clinicopathological and genetic features of prostate cancer in Algerian patients: First report
Abstract 4602: Clinicopathological and genetic features of prostate cancer in Algerian patients: First report
Abstract
Background: Prostate cancer is the second most frequent malignancy (after lung cancer) in men worldwide. It is the third most common cancer in men in Algeri...
In situ Generated 212Pb-PSMA Ligand in a 224Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive Cells
In situ Generated 212Pb-PSMA Ligand in a 224Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive Cells
Background:
New treatments combating bone and extraskeletal metastases are needed for
patients with metastatic castration-resistant prostate cancer. The majority of metastases over...
Utility of PET to Appropriately Select Patients for PSMA-Targeted Theranostics
Utility of PET to Appropriately Select Patients for PSMA-Targeted Theranostics
Abstract
The majority of aggressive prostate cancers overexpress the transmembrane protein prostate-specific membrane antigen (PSMA). PSMA is, therefore, an attractive ta...

